Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
STAA 
STAAR Surgical Company (STAA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/11/2025: STAA (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 2.51% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 868.13M USD | Price to earnings Ratio - | 1Y Target Price 18.67 |
Price to earnings Ratio - | 1Y Target Price 18.67 | ||
Volume (30-day avg) 1345498 | Beta 0.66 | 52 Weeks Range 13.50 - 52.68 | Updated Date 04/1/2025 |
52 Weeks Range 13.50 - 52.68 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.41 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -6.44% | Operating Margin (TTM) -56.89% |
Management Effectiveness
Return on Assets (TTM) -1.55% | Return on Equity (TTM) -5.16% |
Valuation
Trailing PE - | Forward PE 625 | Enterprise Value 676375547 | Price to Sales(TTM) 2.77 |
Enterprise Value 676375547 | Price to Sales(TTM) 2.77 | ||
Enterprise Value to Revenue 2.15 | Enterprise Value to EBITDA 42.84 | Shares Outstanding 49325400 | Shares Floating 33955913 |
Shares Outstanding 49325400 | Shares Floating 33955913 | ||
Percent Insiders 0.55 | Percent Institutions 108.4 |
Analyst Ratings
Rating 3.93 | Target Price 40.98 | Buy 1 | Strong Buy 7 |
Buy 1 | Strong Buy 7 | ||
Hold 5 | Sell - | Strong Sell 1 | |
Strong Sell 1 |
Upturn AI SWOT
STAAR Surgical Company
Company Overview
History and Background
STAAR Surgical Company was founded in 1982. Initially focused on various ophthalmic products, it has evolved to specialize in implantable lenses for refractive vision correction, primarily the Visian ICL.
Core Business Areas
- Implantable Lenses: Develops, manufactures, and markets the Visian ICL (Implantable Collamer Lens) for the correction of myopia, hyperopia, and astigmatism.
Leadership and Structure
The company is led by Tom Frinzi (CEO). The organizational structure is typical of a medical device company, with departments focused on R&D, manufacturing, sales, marketing, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Visian ICL: The Visian ICL is STAAR Surgical's primary product. It's a phakic intraocular lens implanted behind the iris and in front of the natural lens to correct refractive errors. Market share is estimated around 25-30% of the global phakic IOL market. Competitors include Alcon (ALC), Johnson & Johnson (JNJ) and Carl Zeiss Meditec (AFX.DE).
Market Dynamics
Industry Overview
The refractive surgery market includes LASIK, PRK, and implantable lenses. The market is growing, driven by increased awareness, technological advancements, and a desire for vision correction without glasses or contacts.
Positioning
STAAR Surgical is positioned as a premium provider of implantable lenses, specifically the Visian ICL. Their competitive advantage lies in the ICL's reversibility, biocompatibility, and ability to correct a wide range of refractive errors.
Total Addressable Market (TAM)
The global refractive surgery market is estimated to be worth billions of dollars annually. STAAR is positioned to grow their market share within the segment of this total market value.
Upturn SWOT Analysis
Strengths
- Proprietary technology (Visian ICL)
- Strong brand reputation in the ICL market
- Growing market demand for refractive surgery
- Global presence
Weaknesses
- Reliance on a single product (Visian ICL)
- Higher cost compared to LASIK
- Dependence on surgeon training and adoption
Opportunities
- Expanding into new geographic markets
- Developing new ICL designs for presbyopia correction
- Increasing awareness through marketing and education
- Capitalizing on the growing Asian market
Threats
- Competition from LASIK and other refractive surgery procedures
- Economic downturns affecting consumer spending
- Technological advancements disrupting the market
- Regulatory changes impacting medical device approvals
Competitors and Market Share
Key Competitors
- ALC
- JNJ
- AFX.DE
Competitive Landscape
STAAR's advantage is the ICL's unique benefits. Disadvantages include higher cost and reliance on surgeon training. Competitors have a broader product portfolio.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: STAAR Surgical has experienced strong revenue growth in recent years, driven by increasing ICL sales.
Future Projections: Analyst estimates project continued revenue growth for STAAR Surgical, driven by market expansion and new product introductions.
Recent Initiatives: Recent initiatives include expanding manufacturing capacity, increasing sales and marketing efforts, and developing new ICL designs.
Summary
STAAR Surgical is a specialized medical device company with a strong position in the implantable lens market, particularly with its Visian ICL. The company has experienced revenue growth in recent years due to increasing ICL sales, but it needs to be aware of threats such as technology and competition. Continued innovation and strategic market expansion will be critical for future success.
Similar Companies
ALC
Alcon AG
ALC
Alcon AG
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
Sources and Disclaimers
Data Sources:
- Company reports
- Analyst reports
- Market research reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is estimated and may vary. Financial data requires review of recent company financial statements.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About STAAR Surgical Company
Exchange NASDAQ | Headquaters Lake Forest, CA, United States | ||
IPO Launch date 1983-07-15 | CEO & Lead Director Mr. Stephen C. Farrell CFA | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 1157 | Website https://www.staar.com |
Full time employees 1157 | Website https://www.staar.com | ||
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) and laser-based procedures, such as LASIK to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.